Selenium for Blood Sugar: What 20 RCTs Actually Found

Selenium may change insulin markers without lowering blood sugar

Selenium does not earn a place as a general-purpose blood-sugar supplement. The best available synthesis found that it lowered fasting insulin and modestly improved an insulin-sensitivity index, but it did not reliably lower fasting glucose, HbA1c, or HOMA-IR. The same review also found a statistically significant nonlinear relationship between selenium dose and fasting blood sugar. Dose matters, but the published abstract does not identify a safe or effective dose range.

That is more useful than the usual selenium debate, which tends to collapse into "helpful antioxidant" versus "diabetes risk." The randomized-trial evidence points to a narrower conclusion: selenium may affect insulin dynamics in some settings, especially among people with existing insulin dysregulation. It has not shown a dependable population-level effect on the glucose numbers most people track.

The strongest evidence: lower fasting insulin, unchanged glucose

A 2023 GRADE-assessed systematic review and dose-response meta-analysis by Vajdi et al. pooled 20 randomized controlled trials of selenium supplementation. Across those trials, fasting insulin fell by a weighted mean difference of 3.02 µIU/mL versus control (95% CI, −5.13 to −0.90; P=0.005). The quantitative insulin sensitivity check index, or QUICKI, increased by 0.01 (95% CI, 0.01 to 0.02; P=0.005).

Those are statistically significant changes in markers of insulin dynamics. They do not establish that selenium prevents diabetes, improves clinical outcomes, or produces a meaningful change for every individual. QUICKI and fasting insulin are useful research markers, but they are not the same as fewer diabetes diagnoses or lower complication rates.

More importantly for anyone watching a glucose monitor, the pooled glucose outcomes were null. Fasting blood sugar changed by −1.32 mg/dL (95% CI, −4.02 to 1.37; P=0.332), HbA1c changed by +0.05 percentage points (95% CI, −0.19 to 0.28; P=0.701), and HOMA-IR changed by −0.82 (95% CI, −2.14 to 0.50; P=0.223). Each confidence interval included no effect.

The HOMA-IR result can look odd beside the fall in fasting insulin, but HOMA-IR incorporates both fasting insulin and fasting glucose. If insulin falls while glucose barely moves, the combined estimate may not shift enough to reach statistical significance. Its wide confidence interval allows for improvement as well as no effect, so it is better read as imprecise than as proof of zero effect.

The dose-response result is real, but it does not prescribe a dose

Vajdi and colleagues found evidence that selenium dose and fasting blood sugar did not follow a straight-line relationship (P for nonlinearity=0.008). In practical terms, more selenium cannot be assumed to produce proportionally more benefit—or proportionally more harm. The relationship bends somewhere across the doses studied.

That finding does not tell a reader where to supplement. The available abstract does not report the curve's shape, its inflection point, or dose thresholds. Any article that turns this P value into a recommended selenium dose is filling in information the analysis did not provide.

There is an additional reason to resist casual high-dose use. A large trial of more than 35,000 participants tested 200 µg/day of selenomethionine and reported increased type 2 diabetes incidence; that trial is an important safety consideration, though its data are not included in the linked evidence reviewed here. Selenium is an essential nutrient, but essential does not mean that extra amounts improve metabolism.

Who might see a signal?

The more encouraging findings come from populations with established insulin resistance or unusually high oxidative-stress burden, not from metabolically healthy adults. In a randomized trial of infertile women with PCOS undergoing IVF, Modarres et al. reported improved glycemic control and oxidative-stress markers with selenium supplementation. PCOS often includes insulin resistance, but one specialized-population trial cannot establish benefit for people without PCOS or fertility treatment.

Gestational-diabetes studies point in the same direction, with a major catch: several tested selenium as part of a combination. An RCT in people with gestational diabetes found improved glycemic status and serum lipoproteins with selenium plus probiotics. A meta-analysis of probiotic-and-selenium co-supplementation trials also reported improved glycemia indices. These results belong to the combination, not selenium alone. Probiotics may have contributed, and the trial designs cannot mathematically separate their effect from selenium's.

Broader gestational-diabetes evidence supports the possibility that micronutrient or antioxidant interventions can help in that setting. A meta-analysis of 12 trials involving 698 women found that several vitamins and minerals, including selenium alone or in combinations, improved glycemic-control measures versus placebo in gestational diabetes. That review did not isolate selenium as the sole explanation for the pooled result. Likewise, a 2025 review of antioxidant supplements in gestational diabetes provides biological context for antioxidant strategies, not proof that selenium alone treats the condition.

Network meta-analyses in type 2 diabetes and PCOS place selenium among many nutritional interventions, but the available results do not provide selenium-specific effect estimates or rankings that would justify choosing it over alternatives. The PCOS network analysis included 41 articles and 2,362 patients, while its reported leading results identified other supplements for specific outcomes. It is comparative context, not a selenium prescription.

Why observational findings complicate the antioxidant story

Selenium biology does not move in one obvious direction. In a prospective pregnancy study, Demircan et al. found that circulating selenoprotein P and glutathione peroxidase 3 measured during early and late pregnancy were associated with gestational-diabetes risk. An association cannot prove that higher selenium status caused gestational diabetes, and pregnancy has its own metabolic physiology. Still, the finding directly challenges the idea that higher selenoprotein activity must improve insulin handling.

A national cross-sectional study of Chinese women older than 45 also found that inflammation mediated associations between selenium status and glucose metabolism. Liu et al. cannot establish cause and effect because the data were collected at one point in time. It does, however, offer a plausible reason selenium trials might differ: baseline inflammation could influence the metabolic response.

Population and physiology also limit generalization. A selenium RCT in diabetic hemodialysis patients examined carotid intima-media thickness and metabolic status, but severe kidney disease changes selenium handling and adds uremic oxidative stress. Those findings should not be treated as a guide for generally healthy adults or ordinary type 2 diabetes.

What the evidence can and cannot support

Selenium supplementation improved fasting insulin and QUICKI across 20 randomized trials, but it did not reliably lower fasting glucose or HbA1c. The dose-response relationship for fasting glucose was nonlinear, and the available report does not reveal the dose range that helps or harms.

For someone with documented insulin resistance, PCOS, or another clinician-managed metabolic condition, selenium is a question worth discussing in the context of diet, selenium status, medications, and pregnancy plans. The RCT signal is strongest for insulin-related markers, not for glucose control itself.

For a selenium-replete, metabolically healthy person seeking lower glucose or HbA1c, the evidence does not support supplementation for that goal. The review also leaves important questions unanswered: selenium form, baseline selenium status, outcome-specific GRADE ratings, and heterogeneity estimates were not available in the published abstract. Until dose and baseline status are clarified, selenium is a narrow, conditional intervention—not a blood-sugar shortcut.